Artiva Biotherapeutics, Inc. Common Stock Total Assets
Artiva Biotherapeutics, Inc. Common Stock total assets. Based on the latest financial reports, Artiva Biotherapeutics, Inc. Common Stock (ARTV) holds total assets worth $148.86 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see cash efficiency ratio of Artiva Biotherapeutics, Inc. Common Stoc for how efficiently the company converts equity into cash flow.
Total Assets of Artiva Biotherapeutics, Inc. Common Stock (2019–2024)
Total assets of Artiva Biotherapeutics, Inc. Common Stock from 2019 to 2024. This chart illustrates how Artiva Biotherapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See ARTV share price today for real-time trading data and today's change.
Artiva Biotherapeutics, Inc. Common Stock - Asset Composition Analysis
Artiva Biotherapeutics, Inc. Common Stock Total Assets Breakdown (December 2024)
Artiva Biotherapeutics, Inc. Common Stock total assets breakdown as of December 2024. Artiva Biotherapeutics, Inc. Common Stock's total assets of $148.86 Million consist of 90.0% current assets and 10.0% non-current assets. Explore Artiva Biotherapeutics, Inc. Common Stoc (ARTV) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.2% |
| Accounts Receivable | $146.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Artiva Biotherapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Artiva Biotherapeutics, Inc. Common Stock's current assets represent 90.0% of total assets in 2024, an increase from 40.6% in 2019.
- Cash Position: Cash and equivalents constituted 19.2% of total assets in 2024, down from 38.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Artiva Biotherapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Artiva Biotherapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Artiva Biotherapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.65 | 11.33 | 6.53 |
| Quick Ratio | 11.65 | 11.33 | 6.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $118.41 Million | $137.27 Million | $67.59 Million |
Artiva Biotherapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Artiva Biotherapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.71 |
| Latest Market Cap to Assets Ratio | 0.40 |
| Asset Growth Rate (YoY) | 99.4% |
| Total Assets | $209.58 Million |
| Market Capitalization | $82.80 Million USD |
Valuation Analysis
Below Book Valuation: The market values Artiva Biotherapeutics, Inc. Common Stock's assets below their book value (0.40x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Artiva Biotherapeutics, Inc. Common Stock's assets grew by 99.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Artiva Biotherapeutics, Inc. Common Stock (2019–2024)
The table below shows the annual total assets of Artiva Biotherapeutics, Inc. Common Stock from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $209.58 Million | +99.38% |
| 2023-12-31 | $105.11 Million | -21.00% |
| 2022-12-31 | $133.05 Million | -21.70% |
| 2021-12-31 | $169.93 Million | +481.26% |
| 2020-12-31 | $29.23 Million | +504.13% |
| 2019-12-31 | $4.84 Million | -- |
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus n… Read more